Calbiotech, a life science company in Spring Valley, has entered a development agreement with La Jolla-based Intrinsic LifeSciences to develop and validate ELISA kits for hepcidin, a hormone that plays a central role in the regulation of iron in the blood and an indicator of iron disorders.
Under the agreement, Calbiotech will produce prototype Intrinsic Hepcidin ELISA kits for technical and clinical validation studies.
Calbiotech develops and manufactures immunoassay products used by labs, universities and research centers around the world. Calbiotech also offers blood, saliva and research animal kits for clinical and pre-clinical testing.
“Calbiotech has established a reputation providing innovative, high quality contract manufacturing services that provides the flexibility to accommodate the needs of our partners,” said David Barka, vice president of Calbiotech. “The strategic partnership with Intrinsic allows us to combine our quality manufacturing expertise with ILS’s experience as pioneers of hepcidin testing; we are a natural fit for the project.”
Intrinsic LifeSciences was awarded a $4.45 million grant last month from the National Institute of Health for its Phase II-B Small Business Innovation Research project.
“We are extremely pleased that NIH has recognized the potential of the Hepcidin Index test for clinical medicine by deciding to fund our pre-commercialization efforts and clinical study.” said principal investigator Mark Westerman, CEO of Intrinsic.